How to pay a healthcare sales force without buying a compliance problem

The commission model that is perfectly lawful for one healthcare product line can be a federal problem on another — under the same roof, sold by the same rep, in the same month. The dividing line is not the product. It is how the product is paid for.

The mistake that repeats

A company brings a sales organization a portfolio: a cash-pay wellness product, a device billed to commercial insurance, and a monitoring service reimbursed by Medicare. The commercial instinct is to put one commission grid across all three. That instinct — uniformity for the sake of administration — is where most healthcare compensation problems begin.

Federal law does not regulate sales commissions as a category. It regulates remuneration intended to induce the purchase of items or services paid for by federal healthcare programs. The Anti-Kickback Statute reaches any arrangement where compensation varies with the volume or value of federally reimbursed business. EKRA reaches recovery homes, clinical treatment facilities, and laboratories with its own rules. Stark constrains physician relationships. None of these laws cares what your org chart calls the payment. All of them care what the payment does.

The framework: classify the line before you design the comp

Cash-pay lines: percentage compensation is available — with screens

Where no federal or state healthcare program pays for the offering — true cash-pay, self-pay product and service lines — the federal Anti-Kickback Statute’s core trigger is absent, and percentage-of-revenue compensation can be structured lawfully. This is why cash-pay wellness, aesthetics, and direct-to-practice product lines commonly run on commission.

“Can be” is doing real work in that sentence. Three screens still apply:

• State law. Patient-brokering, fee-splitting, and consumer-protection statutes operate independently of federal reimbursement, vary widely by state, and reach some cash-pay arrangements.
• Line drift. A line that is cash-pay today can become reimbursable tomorrow. A disciplined arrangement states, in writing, that no commission is earned on any transaction actually billed to a federal program — and converts the model before further sales if the line’s status changes.
• Product legality. A lawful commission on an unlawful product is not a compliance posture. Each SKU’s regulatory status deserves written confirmation before the first sales call, not after the first demand letter.

Federally reimbursed lines: fixed fair-market-value fees

Where Medicare, Medicaid, TRICARE, or another federal program pays for the offering — in whole or in part — volume-based compensation to an independent sales organization invites exactly the scrutiny the safe harbors were written to avoid. The defensible structure is a fixed fee, set in advance at fair market value, under the Personal Services and Management Contracts safe harbor: compensation that does not move with volume, supported by independent FMV documentation, refreshed on a schedule and on material scope change.

There is one important nuance: the Bona Fide Employee safe harbor treats W-2 employees differently from independent contractors. A company may have more flexibility in how it incentivizes its own employees than in how it compensates an outside sales organization. Arrangements that respect that boundary — fixed FMV fees at the organization-to-organization layer, employee incentives handled inside the employer relationship — are materially easier to defend than arrangements that blur it.

Contingency and recovery services: a category of their own

Selling revenue-integrity or underpayment-recovery services on a share of the recovery adds a second layer: the lawfulness of the underlying recovery methods. A sales organization taking a percentage of a contingency fee should insist on warranties about how the recoveries are generated, take no part in claims, coding, or billing work itself, and address False Claims Act and state fee-splitting exposure in the agreement — before the first client is introduced.

What a defensible arrangement looks like on paper

Across every model, the arrangements that survive review share the same anatomy:

1. A written agreement that states the model, the rate, the territory, and the term — signed before services begin.
2. FMV documentation for any fixed-fee arrangement, from an independent source, on file with both parties, refreshed on a defined cadence.
3. Attribution rules — who sourced which customer, recorded where, surviving how long — so compensation can be traced to legitimate services rendered.
4. Approved-claims discipline. The sales force says only what the product’s owner has substantiated and approved. Marketing claims are a regulatory surface, not a creative one.
5. A conversion clause. What happens when a line’s reimbursement status changes, stated in advance — because it will.

If an arrangement cannot be explained to a regulator in one page, it is not an arrangement worth running.

The question for your next channel deal

Before the rate negotiation, ask the structural question: for each line in this portfolio, who pays for it — and does this compensation model match that answer? Companies that ask it up front design once. Companies that skip it design twice: once for the launch, and once for the lawyers.